ecancer· @ecancer · X·· 22 小时前评分70
正文 · 机器翻译
AZUR-1：Dostarlimab 单药治疗在 dMMR/MSI-H 局部晚期直肠癌患者中，12 个月时实现了 68% 的持续完全缓解。免疫疗法能否让患者免于化疗、放疗和手术？点击此处观看👉https://ow.ly/wqVQ5100Vg6 @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer
19 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1270P按 Gynaecological cancers 对上
Differential immune profiling of short- and long-responders to dostarlimab in recurrent or advanced mismatch repair-deficient endometrial cancer
https://esmocongress.esmo.org2877RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study
https://esmocongress.esmo.org来源：ecancer · x.com